Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia

/PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB...

Related Keywords

China ,Beijing ,Boston ,Massachusetts ,United States ,Australia ,Shanghai ,Haimen Jiangsu ,Yuelei Shen ,Eucure Biopharma ,Biocytogen Pharmaceuticals Beijing Co Ltd ,Biocytogen ,